未进行透析的肾衰竭患者中头孢唑肟的药代动力学
Pharmacokinetics of ceftizoxime in renal failure patients without dialysis.
作者信息
Li P, Cai Q, Gao S, Liu G L, Cui R L, Yang X Y
机构信息
Clinical Pharmacology Unit, Changhai Hospital, Shanghai, China.
出版信息
Zhongguo Yao Li Xue Bao. 1995 Sep;16(5):402-4.
AIM
To investigate the pharmacokinetics of ceftizoxime (Cef) in renal failure patients without any dialysis and supply the basis for a suitable clinical regimen.
METHODS
Cef in plasma and urine was assayed by HPLC.
RESULTS
After injecting Cef 16.7 mg kg-1, Cef concentration in blood was described as a 2-compartment open model. The main pharmacokinetic parameters were Vd 0.55 +/- 0.17 L kg-1; AUC 879 +/- 460 mg L-1 h; Cl 27 +/- 11 mL kg-1 h-1. T1/2 beta was 15 +/- 4 h.
CONCLUSION
T1/2 beta in renal failure patients was about 10 times longer than that in normal volunteers. The clinical regimen should be adjusted in renal failure patients with infection, either prolonging the interval between Cef administration, or decreasing Cef dosage.
目的
研究头孢唑肟（Cef）在未进行任何透析的肾衰竭患者体内的药代动力学，为合适的临床用药方案提供依据。
方法
采用高效液相色谱法测定血浆和尿液中的头孢唑肟。
结果
静脉注射头孢唑肟16.7mg/kg后，血药浓度符合二室开放模型。主要药代动力学参数为：分布容积（Vd）0.55±0.17L/kg；药时曲线下面积（AUC）879±460mg·L-1·h；清除率（Cl）27±11mL·kg-1·h-1。β相半衰期（T1/2β）为15±4小时。
结论
肾衰竭患者的β相半衰期约为正常志愿者的10倍。对于感染的肾衰竭患者，临床用药方案应进行调整，可延长头孢唑肟给药间隔或减少给药剂量。
Zotero 插件